Insight Molecular Diagnostics (IMDX) Assets Average (2016 - 2026)

Insight Molecular Diagnostics (IMDX) has 11 years of Assets Average data on file, last reported at $33.1 million in Q1 2026.

• Quarterly Assets Average fell 30.66% year-over-year to $33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.1 million (down 30.66% YoY) and the FY2025 annual result came in at $30.4 million, down 44.68% from the prior year.
• Assets Average eased to $33.1 million in Q1 2026 per IMDX's latest filing, from $34.8 million in the prior quarter.
• The five-year high for Assets Average was $164.2 million in Q3 2022, with the low at $33.1 million in Q1 2026.
• Average Assets Average over 5 years is $84.3 million, with a median of $72.9 million recorded in 2024.
• Year-over-year, Assets Average soared 65.56% in 2022 and tumbled 48.5% in 2023.
• Insight Molecular Diagnostics' Assets Average stood at $128.7 million in 2022, then slumped by 39.22% to $78.2 million in 2023, then sank by 32.71% to $52.6 million in 2024, then sank by 33.81% to $34.8 million in 2025, then dropped by 5.04% to $33.1 million in 2026.
• Business Quant data shows IMDX's Assets Average at $33.1 million in Q1 2026, $34.8 million in Q4 2025, and $47.2 million in Q3 2025.